title: Benefits of early glycemic control by insulin on sensory neuropathy and cataract in diabetic rats.
abstract: While there is an emphasis on the early glycemic control for its long-term benefits in preventing microvascular complications of diabetes, the biochemical mechanisms responsible for the long-lasting effects are not clearly understood. Therefore the impact of early insulin (EI) versus late insulin (LI) treatment on diabetic sensory neuropathy and cataract in streptozotocin-induced diabetic Wistar male rats were evaluated. EI group received insulin (2.5 IU/animal, once daily) treatment from day 1 to 90 while LI group received insulin from day 60 to 90. Early insulin treatment significantly reduced the biochemical markers like glucose, triglyceride, glycated hemoglobin, thiobarbituric acid reactive substances, advanced glycation end products and ratio of reduced glutathione and oxidized glutathione in diabetic rats. The late insulin treatment failed to resist the biochemical changes in diabetic rats. Diabetic rats developed sensory neuropathy as evidenced by mechanical and thermal hyperalgesia and showed a higher incidence and severity of cataract as revealed by slit lamp examination. Early insulin treatment protected the rats from the development of neuropathy and cataract, but late insulin administration failed to do so. The results demonstrate the benefits of early glycemic control in preventing neuropathy and cataract development in diabetic rats.
authors: Department of Cell and Molecular Biology, Madras Diabetes Research Foundation, Dr.Mohan's Diabetes Specialties Centre & IDF Centre of Education, Gopalapuram, Chennai 600 086, India.
authors: Mahalingam
authors: M
authors: Balakumar
authors: Natarajan
authors: N
authors: Saravanan
authors: Durai
authors: D
authors: Prabhu
authors: Bhaskaran
authors: B
authors: Regin
authors: G Bhanuprakash
authors: GB
authors: Reddy
authors: Viswanathan
authors: V
authors: Mohan
authors: Mohan
authors: M
authors: Rema
authors: Muthuswamy
authors: M
authors: Balasubramanyam
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002386:Cataract / Q000378:metabolism; D048909:Diabetes Complications / Q000378:metabolism*; D003921:Diabetes Mellitus, Experimental / Q000628:therapy; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000517:prevention & control*; D004195:Disease Models, Animal; D005978:Glutathione / Q000378:metabolism; D017127:Glycation End Products, Advanced; D006943:Hyperglycemia / Q000628:therapy; D007328:Insulin / Q000378:metabolism; D007908:Lens, Crystalline / Q000378:metabolism; D015227:Lipid Peroxidation; D008297:Male; D017288:Pain Threshold; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001786:Blood Glucose; D017127:Glycation End Products, Advanced; D007328:Insulin; D005978:Glutathione